- Home
- ABCL
as of 06-05-2026 3:46pm EST
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
| Founded: | 2012 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 1.3B | IPO Year: | 2020 |
| Target Price: | $8.40 | AVG Volume (30 days): | 8.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.14 | EPS Growth: | 10.91 |
| 52 Week Low/High: | $2.45 - $6.79 | Next Earning Date: | 05-11-2026 |
| Revenue: | $75,128,000 | Revenue Growth: | 160.56% |
| Revenue Growth (this year): | -58.53% | Revenue Growth (next year): | 21.85% |
| P/E Ratio: | -45.50 | Index: | N/A |
| Free Cash Flow: | -174067000.0 | FCF Growth: | N/A |
AI-Powered ABCL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 24, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 24, 2026 · 100% conf.
1D
-5.86%
$3.05
Act: -1.87%
5D
-8.39%
$2.97
Act: +14.51%
20D
-10.45%
$2.90
abcl-202602240001703057falseVancouverBC00017030572026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 24, 2026
AbCellera Biologics Inc. (Exact name of registrant as specified in its charter)
British Columbia001-39781Not Applicable (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition On February 24, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD In connection with its earnings call on February 24, 2026, to discuss its results for the year ended December 31, 2025, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2. The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release issued by AbCellera Biologics Inc. on February 24, 2026.
99.2Corporate Presentation.
104Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 24, 2026ABCELLERA BIOLOGICS INC.
By:/s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
abcl-202511060001703057falseVancouverBC00017030572025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 6, 2025
AbCellera Biologics Inc. (Exact name of registrant as specified in its charter)
British Columbia001-39781Not Applicable (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition On November 6, 2025, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure In connection with its earnings call on November 6, 2025, to discuss its results for the quarter ended September 30, 2025, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2. The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release issued by AbCellera Biologics Inc. on November 6, 2025.
99.2Corporate presentation.
104Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 6, 2025
ABCELLERA BIOLOGICS INC.
By:/s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
Q2 2025 Earnings
8-KAug 7, 2025
abcl-202508070001703057falseVancouverBC00017030572025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 7, 2025
AbCellera Biologics Inc. (Exact name of registrant as specified in its charter)
British Columbia001-39781Not Applicable (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition On August 7, 2025, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended August 7, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure In connection with its earnings call on August 7, 2025, to discuss its results for the quarter ended June 30, 2025, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2. The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release issued by AbCellera Biologics Inc. on August 7, 2025.
99.2Corporate presentation.
104Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 7, 2025
ABCELLERA BIOLOGICS INC.
By:/s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)
Compare ABCL vs Leading Stocks
See how ABCL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABCL AbCellera Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.